BR0213154A - Compostos de glicopeptìdeo - cefalosporina de ligação reticulada, composições farmacêuticas de tais compostos, método de fabricação dos mesmos e seus usos - Google Patents

Compostos de glicopeptìdeo - cefalosporina de ligação reticulada, composições farmacêuticas de tais compostos, método de fabricação dos mesmos e seus usos

Info

Publication number
BR0213154A
BR0213154A BR0213154-4A BR0213154A BR0213154A BR 0213154 A BR0213154 A BR 0213154A BR 0213154 A BR0213154 A BR 0213154A BR 0213154 A BR0213154 A BR 0213154A
Authority
BR
Brazil
Prior art keywords
compounds
pharmaceutical compositions
cross
manufacture
cephalosporin
Prior art date
Application number
BR0213154-4A
Other languages
English (en)
Inventor
Paul Ross Fatheree
Martin Linsell
Daniel D Long
Daniel Marquess
Edmund J Moran
Matthew Nodwell
S Derek Turner
James Aggen
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of BR0213154A publication Critical patent/BR0213154A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
    • C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

"COMPOSTOS DE GLICOPEPTìDEO - CEFALOSPORINA DE LIGAçãO RETICULADA, COMPOSIçõES FARMACêUTICAS DE TAIS COMPOSTOS, MéTODO DE FABRICAçãO DOS MESMOS E SEUS USOS". Essa invenção fornece compostos de glicopeptídeo cefalosporina de ligação reticulada e sais farmaceuticamente aceitáveis destes que são úteis como antibióticos. Essa invenção também fornece composições farmacêuticas contendo tais compostos; métodos para o tratamento de infecções bacterianas em um mamífero usando tais compostos; e processos e intermediários úteis para a preparação de tais compostos.
BR0213154-4A 2001-10-12 2002-10-11 Compostos de glicopeptìdeo - cefalosporina de ligação reticulada, composições farmacêuticas de tais compostos, método de fabricação dos mesmos e seus usos BR0213154A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32888901P 2001-10-12 2001-10-12
PCT/US2002/032534 WO2003031449A2 (en) 2001-10-12 2002-10-11 Cross-linked glycopeptide-cephalosporin antibiotics

Publications (1)

Publication Number Publication Date
BR0213154A true BR0213154A (pt) 2004-08-10

Family

ID=23282891

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0213154-4A BRPI0213154B1 (pt) 2001-10-12 2002-10-11 Compostos de glicopeptídeo — cefalosporina de ligação reticulada, composição farmacêutica de tais compostos e seu uso
BR0213154-4A BR0213154A (pt) 2001-10-12 2002-10-11 Compostos de glicopeptìdeo - cefalosporina de ligação reticulada, composições farmacêuticas de tais compostos, método de fabricação dos mesmos e seus usos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0213154-4A BRPI0213154B1 (pt) 2001-10-12 2002-10-11 Compostos de glicopeptídeo — cefalosporina de ligação reticulada, composição farmacêutica de tais compostos e seu uso

Country Status (30)

Country Link
US (11) US6974797B2 (pt)
EP (1) EP1434779B1 (pt)
JP (3) JP4249023B2 (pt)
KR (1) KR100888660B1 (pt)
CN (2) CN100358901C (pt)
AT (1) ATE314376T1 (pt)
AU (1) AU2002332111B2 (pt)
BR (2) BRPI0213154B1 (pt)
CA (1) CA2463544C (pt)
CO (1) CO5580782A2 (pt)
DE (1) DE60208404T2 (pt)
DK (1) DK1434779T3 (pt)
EA (1) EA007001B1 (pt)
ES (1) ES2254738T3 (pt)
HK (1) HK1066007A1 (pt)
HR (1) HRP20040243B1 (pt)
HU (1) HU230158B1 (pt)
IL (2) IL160846A0 (pt)
IS (1) IS2422B (pt)
MX (1) MXPA04003273A (pt)
NO (1) NO334092B1 (pt)
NZ (1) NZ531576A (pt)
PL (1) PL209757B1 (pt)
RS (1) RS50888B (pt)
SI (1) SI1434779T1 (pt)
SK (1) SK2052004A3 (pt)
TW (1) TWI335332B (pt)
UA (1) UA80098C2 (pt)
WO (1) WO2003031449A2 (pt)
ZA (1) ZA200402732B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI335332B (en) * 2001-10-12 2011-01-01 Theravance Inc Cross-linked vancomycin-cephalosporin antibiotics
JP4347799B2 (ja) * 2002-05-24 2009-10-21 セラヴァンス， インコーポレーテッド 架橋グリコペプチド−セファロスポリン抗生物質
ATE450540T1 (de) 2003-05-23 2009-12-15 Theravance Inc Quervernetzte glycopeptid-cephalosporin- antibiotika
US7067482B2 (en) * 2003-07-11 2006-06-27 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
KR100808414B1 (ko) * 2004-06-08 2008-02-29 엘지전자 주식회사 이동단말의 클라이언트 세션 복구방법
US20060105941A1 (en) * 2004-11-12 2006-05-18 Allergan, Inc. Mixed antibiotic codrugs
CA2848012A1 (en) 2011-09-09 2013-03-14 Cubist Pharmaceuticals, Inc. Methods for treating intrapulmonary infections
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
EP2970164B1 (en) * 2013-03-13 2017-05-03 Theravance Biopharma Antibiotics IP, LLC Crystalline form of a substituted thiazolylacetic acid triethylamine salt
ME02854B (me) 2013-03-13 2018-04-20 Theravance Biopharma Antibiotics Ip Llc Hidrohloridne soli antibiotskog jedinjenja
US20140274989A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Manufacturing beta-lactam combination products
US20140274997A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Cephalosporin pharmaceutical compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
ES2800603T3 (es) 2013-09-09 2021-01-04 Merck Sharp & Dohme Tratamiento de infecciones con ceftolozano/tazobactam en sujetos con insuficiencia renal
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
US10943049B2 (en) * 2018-09-28 2021-03-09 Taiwan Semiconductor Manufacturing Co., Ltd. Rule check violation prediction systems and methods
US11878958B2 (en) 2022-05-25 2024-01-23 Ikena Oncology, Inc. MEK inhibitors and uses thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US457926A (en) * 1891-08-18 Steam-engine
US4668783A (en) * 1974-12-19 1987-05-26 Takeda Chemical Industries, Ltd. Thiazolylacetamido cephalosporin compounds
FR2347706A1 (fr) * 1976-04-08 1977-11-04 Issec Labo Physicochimie Appli Nouveau procede photographique d'impression en couleurs sur divers substrats
JPS5994B2 (ja) * 1976-09-14 1984-01-05 富士写真フイルム株式会社 感光性組成物
US4155909A (en) * 1977-06-13 1979-05-22 Philip Morris Incorporated 2-Alkyl nicotinoids and processes for their production
DE2758001A1 (de) 1977-12-24 1979-07-12 Hoechst Ag Cephalosporinderivate und verfahren zu ihrer herstellung
US4284631A (en) 1978-07-31 1981-08-18 Fujisawa Pharmaceutical Co., Ltd. 7-Substituted cephem compounds and pharmaceutical antibacterial compositions containing them
US4341775A (en) 1978-09-11 1982-07-27 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
GB2033377B (en) 1978-09-11 1983-05-05 Fujisawa Pharmaceuticalco Ltd Cephem compounds and processes for preparation thereof
US4220761A (en) 1978-09-12 1980-09-02 Fujisawa Pharmaceutical Co., Ltd. 7-[Substituted oximinoacetamido]-3-[hydroxy alkyltetrazolo]cephalosporin derivatives
DE3006888A1 (de) * 1980-02-23 1981-09-10 Hoechst Ag, 6000 Frankfurt Cephalosporinderivate und verfahren zu ihrer herstellung
US4427677A (en) * 1980-12-31 1984-01-24 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
DE3118732A1 (de) * 1981-05-12 1982-12-02 Hoechst Ag, 6000 Frankfurt Cephalosporinderivate und verfahren zu ihrer herstellung
JPS5859991A (ja) * 1981-09-14 1983-04-09 Fujisawa Pharmaceut Co Ltd 新規セフェム化合物
US4427877A (en) * 1981-09-28 1984-01-24 Raychem Corporation Printing on low surface energy polymers
DE3207840A1 (de) * 1982-03-04 1983-09-15 Hoechst Ag, 6230 Frankfurt "cephalosporinderivate und verfahren zu ihrer herstellung"
DE3316798A1 (de) * 1983-05-07 1984-11-08 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von cephemverbindungen
JPS6041682A (ja) 1983-08-16 1985-03-05 Meiji Seika Kaisha Ltd 新規セフアロスポリン化合物及びその製造法
DE3418482A1 (de) * 1984-05-18 1985-11-21 Basf Ag, 6700 Ludwigshafen Magnetische aufzeichnungstraeger
US4840945A (en) * 1985-04-01 1989-06-20 Mochida Pharmaceutical Co., Ltd. Cephalosporin derivatives
US4921851A (en) 1986-06-09 1990-05-01 Takeda Chemical Industries, Ltd. Cephem compounds, their production and use
AU1630988A (en) 1987-05-30 1988-12-01 Kyoto Pharmaceutical Industries, Ltd. Cephalosporin compound and pharmaceutical composition thereof
US4974797A (en) * 1988-03-17 1990-12-04 Consolidated Rail Corporation Hot bearing simulator
US4943587A (en) * 1988-05-19 1990-07-24 Warner-Lambert Company Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues and their use for cyclooxygenase and 5-lipoxygenase inhibition
US5693791A (en) * 1995-04-11 1997-12-02 Truett; William L. Antibiotics and process for preparation
AUPN955596A0 (en) * 1996-04-30 1996-05-23 Fujisawa Pharmaceutical Co., Ltd. New compound
JP3906938B2 (ja) * 1997-02-18 2007-04-18 富士フイルム株式会社 画像再生方法及び画像データ管理方法
WO1999042476A1 (en) 1998-02-20 1999-08-26 Advanced Medicine, Inc. Novel antibacterial agents
US6437119B1 (en) * 1998-05-07 2002-08-20 William Lawrence Truett Compounds formed from two or three antibiotics and their processes of preparation
EP1085846A2 (en) * 1998-06-08 2001-03-28 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
CA2336445C (en) * 1998-12-23 2011-07-19 Advanced Medicine, Inc. Glycopeptide derivatives and pharmaceutical compositions containing the same
EP1210769A1 (en) 1999-04-19 2002-06-05 Attila Lenkehegyi Dually adjustable electromechanical means for handling and system of these, and dually adjustable digital potentiometer
US20070154948A1 (en) * 1999-05-24 2007-07-05 Christensen Burton G Novel antibacterial agents
DE60103991T2 (de) 2000-04-06 2005-08-25 Unomedical A/S Verbindungsvorrichtung
JP4107792B2 (ja) * 2000-08-28 2008-06-25 独立行政法人科学技術振興機構 可視光応答性を有する金属オキシナイトライドからなる光触媒
US6885138B1 (en) * 2000-09-20 2005-04-26 Samsung Electronics Co., Ltd. Ferroelectric emitter
US7087482B2 (en) * 2001-01-19 2006-08-08 Samsung Electronics Co., Ltd. Method of forming material using atomic layer deposition and method of forming capacitor of semiconductor device using the same
US20030009681A1 (en) * 2001-07-09 2003-01-09 Shunji Harada Digital work protection system, recording medium apparatus, transmission apparatus, and playback apparatus
TWI335332B (en) * 2001-10-12 2011-01-01 Theravance Inc Cross-linked vancomycin-cephalosporin antibiotics
JP4347799B2 (ja) 2002-05-24 2009-10-21 セラヴァンス， インコーポレーテッド 架橋グリコペプチド−セファロスポリン抗生物質
ATE450540T1 (de) 2003-05-23 2009-12-15 Theravance Inc Quervernetzte glycopeptid-cephalosporin- antibiotika
US7067482B2 (en) * 2003-07-11 2006-06-27 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
CN100352223C (zh) * 2004-12-31 2007-11-28 华为技术有限公司 一种在城域传输网络中保护数据业务的方法
WO2009076399A2 (en) 2007-12-11 2009-06-18 Theravance, Inc. Aminotetralin compounds as mu opioid receptor antagonists

Also Published As

Publication number Publication date
TWI335332B (en) 2011-01-01
US20100197569A1 (en) 2010-08-05
JP2009143962A (ja) 2009-07-02
US20080045721A1 (en) 2008-02-21
IS7172A (is) 2004-03-04
NZ531576A (en) 2006-10-27
PL209757B1 (pl) 2011-10-31
US7655621B2 (en) 2010-02-02
US20030130173A1 (en) 2003-07-10
WO2003031449A2 (en) 2003-04-17
US20080039374A1 (en) 2008-02-14
EA200400530A1 (ru) 2004-08-26
US7612037B2 (en) 2009-11-03
CA2463544A1 (en) 2003-04-17
EA007001B1 (ru) 2006-06-30
DE60208404D1 (de) 2006-02-02
CN1781916A (zh) 2006-06-07
DK1434779T3 (da) 2006-01-30
CA2463544C (en) 2011-03-29
HRP20040243B1 (en) 2008-07-31
KR100888660B1 (ko) 2009-03-13
EP1434779B1 (en) 2005-12-28
US20080194465A1 (en) 2008-08-14
HRP20040243A2 (en) 2004-08-31
NO334092B1 (no) 2013-12-09
ES2254738T3 (es) 2006-06-16
US20080194464A1 (en) 2008-08-14
WO2003031449A3 (en) 2003-08-28
HUP0401596A3 (en) 2013-06-28
SI1434779T1 (sl) 2006-06-30
YU29504A (sh) 2006-08-17
ZA200402732B (en) 2005-05-25
DE60208404T2 (de) 2006-07-27
CN1329397C (zh) 2007-08-01
US20120214967A1 (en) 2012-08-23
HK1066007A1 (en) 2005-03-11
JP2005507907A (ja) 2005-03-24
NO20041912L (no) 2004-05-10
US7713931B2 (en) 2010-05-11
US20080051577A1 (en) 2008-02-28
IS2422B (is) 2008-10-15
US20050239691A1 (en) 2005-10-27
JP4445028B2 (ja) 2010-04-07
CN100358901C (zh) 2008-01-02
IL160846A0 (en) 2004-08-31
EP1434779A2 (en) 2004-07-07
US7341993B2 (en) 2008-03-11
PL368451A1 (en) 2005-03-21
US20080039611A1 (en) 2008-02-14
IL160846A (en) 2010-05-17
ATE314376T1 (de) 2006-01-15
US8557978B2 (en) 2013-10-15
AU2002332111B2 (en) 2008-04-17
UA80098C2 (en) 2007-08-27
HU230158B1 (hu) 2015-09-28
US7553962B2 (en) 2009-06-30
US8044195B2 (en) 2011-10-25
US7649080B2 (en) 2010-01-19
CN1568325A (zh) 2005-01-19
US6974797B2 (en) 2005-12-13
HUP0401596A2 (hu) 2004-12-28
JP2009040795A (ja) 2009-02-26
JP4249023B2 (ja) 2009-04-02
US20080108558A1 (en) 2008-05-08
US7728127B2 (en) 2010-06-01
US7601690B2 (en) 2009-10-13
BRPI0213154B1 (pt) 2018-01-16
SK2052004A3 (en) 2004-10-05
CO5580782A2 (es) 2005-11-30
MXPA04003273A (es) 2004-07-08
KR20050035122A (ko) 2005-04-15
RS50888B (sr) 2010-08-31

Similar Documents

Publication Publication Date Title
BR0213154A (pt) Compostos de glicopeptìdeo - cefalosporina de ligação reticulada, composições farmacêuticas de tais compostos, método de fabricação dos mesmos e seus usos
IL165715A0 (en) 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
BR9710768A (pt) Composto composi-Æo e processos para tratamento de infec-{es bacterianas em um mamifero hospedeiro com necessidade de tal tratamento e para prepara-Æo de 6-0-metileritromicina forma i
BR0210016A (pt) Heterociclos bicìclicos contendo nitrogênio, para uso como antibacterianos
NO20042271L (no) Formuleringer som inneholder en cefalosporinforbindelse og deres anvendelse for behandling av bakterielle infeksjoner i katter og hunder
DE602004012269D1 (de) Quervernetzte glycopeptid-cephalosporin-antibiotika
MA25009A1 (fr) Procede de preparation de composes derives de la piperidine pour la preparation de compositions antibacteriennes
TW200734344A (en) Antibacterial agents
BRPI0413234A (pt) derivados de imidazola bicìclica contra flaviviridae
BR9802851A (pt) Antibióticos de macrolìdeo substituìdos por c-4
EA200000594A1 (ru) Новые макролиды
DE602004024393D1 (de) Quervernetzte glycopeptid-cephalosporin-antibiotika
EA199901016A1 (ru) 9-оксим-производные эритромицина
BR0010938A (pt) Derivados da 13-metil eritromicina
WO2006120563A3 (en) Antibacterial agents
EA200400086A1 (ru) Новые производные оксазолидинонов в качестве антибактериальных агентов
BR9610527A (pt) Novos derivados de substâncias de ciclodepsipeptìdeo pf1022
ATE556088T1 (de) Konjugat beinhaltend cephalosporin und glykopeptidantibiotikum
PT1057828E (pt) Suspensoes de trovafloxacina para administracao oral
DK1007530T3 (da) 6-O-substituerede erythromycinforbindelser samt fremgangsmåde til fremstilling heraf
DK1309336T3 (da) Laspartomycin-derivater og fremstilling og anvendelse deraf
ATE328898T1 (de) Chemotaxis hemmendes protein von staphylococcus aureus (chips) und dessen verwendung
BRPI0410967A (pt) compostos, composições e seus usos para o tratamento de infecções por vìrus da famìlia flaviviridae
NO20042711L (no) Fremgangsmate for a behandle bakterielle infeksjoner ved anvendelse av gemifloksasin eller et salt derav et betalaktamantibiotikum
BR0307468A (pt) Derivados tiadiazinona antimicrobianos úteis no tratamento de infecções bacterianas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. C07D 501/00; C07K 9/00; C07D 501/20; A61K 31/545; A61K 38/04; A61P 31/00; A61P 31/04

Ipc: C07D 501/00 (2011.01), C07K 9/00 (2011.01), C07D 5

B25A Requested transfer of rights approved

Owner name: THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06J Correction of requirement [chapter 6.10 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2599 DE 27-10-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.